Staphylococcus aureus - NRS71
Other designations ( Sanger 252 )
|
|
|
| Demographic Information: |
|
| Country/State: |
United Kingdom |
Date of Isolation: |
01/01/1997 |
| Patient Age: |
64 Year(s) |
Gender: |
Female |
| Patient Location: |
N/A |
Patient Service: |
N/A |
| Culture Source: |
Bloodstream |
|
| Phenotypic Properties: |
N/A
|
|
| Genotypic Properties: |
N/A
|
|
|
| Literature Citation: |
Holden, Matthew T.G. et al. Complete genomes of two clinical Staphylococcus aureus strains: Evidence for the rapid evolution of virulence and drug resistance. PNAS June 29,2004;101(26):9786-9791.
|
|
| Comment: |
N/A
|
| |
| Description: |
Epidemic MRSA strain sequenced at Sanger Centre, UK
|
|
| Repositories: |
Genome Sequenced Strains
|
|
|
|
S = Susceptible; R = Resistant; NS = Not Susceptible; I =Intermediate; N/A = Not Available P= Pending results |
|
|
NARSA Antimicrobial Profile for Other Antimicrobial Agents
|
|
Molecular Characterization Data
|
|
| Ciprofloxacin |
> 16 |
R |
| Clindamycin |
> 4 |
R |
| Erythromycin |
> 8 |
R |
| Gentamicin |
= 0.5 |
S |
| Linezolid |
= 1 |
S |
| Oxacillin |
> 16 |
R |
| Penicillin |
> 2 |
R |
| Quinupristin/dalfopristin |
= 1 |
S |
| Teicoplanin |
= 0.5 |
S |
| Trimeth/sulfa |
<= 0.25/4.75 |
S |
| Vancomycin |
= 0.5 |
S |
|
|
|
|
|
|
|
|
